Invizius, a University of Edinburgh spinout company focused on dialysis technology, secured £500k in funding.
Mercia Fund Managers made the investment, which is the first deal since its partnership with the University of Edinburgh was announced in November 2017.
The company intends to use the funds to build its team and take the product to the next stage of development in preparation for clinical trials.
Based on years of research by biologist Dr Andy Herbert (CTO) and his team, and led by CEO Richard Boyd, Invizius is advaincing a solution to reduce the risk of cardiovascular disease among patients undergoing long-term dialysis.
Its H-Guard™ product is an anti-inflammatory used as a ‘primer’ to coat the filter surface which, when mixed with the patient’s blood, makes the surface seem less foreign to the patient’s immune system.
While the first product is aimed at kidney dialysis, there is also potential to use the technology with other devices or procedures such as catheters, stents, organ transplants and vascular grafts.